Astrana Health sales surge 56% in 2025 as accounting delay clouds record results
Astrana Health (NASDAQ:ASTH) delivered a year of explosive scale in 2025, according to financial results released Monday, with total revenue reaching $3.18 billion.
United StatesHealth
FDA grants priority review to Takeda's first-in-class blood disorder treatment
Takeda (NYSE:TAK) and Protagonist Therapeutics (NASDAQ:PTGX) secured a major regulatory milestone on Monday as the U.S. Food and Drug Administration (FDA) granted Priority Review to rusfertide, an investigational treatment for polycythemia vera (PV).
Health
Alaunos reports early obesity data for oral non-hormonal candidate
Alaunos Therapeutics (NASDAQ:TCRT) released proof-of-concept data from two separate diet-induced obesity (DIO) mouse studies on Monday, marking a strategic pivot toward non-hormonal metabolic treatments.
Health
Ocugen completes Phase 3 enrollment for gene-agnostic retinitis pigmentosa therapy
Ocugen (NASDAQ:OCGN) announced Monday that it has completed patient enrollment for its pivotal Phase 3 liMeliGhT clinical trial, evaluating OCU400 for the treatment of retinitis pigmentosa (RP).
Health
Pharvaris shares "injectable-like" results for oral HAE drug at AAAAI 2026
Pharvaris (NASDAQ:PHVS) dominated the clinical spotlight at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 meeting on Monday, unveiling full data from its RAPIDe-3 and CHAPTER-1 trials.
Health
Apogee Therapeutics eyes 2026 Phase 3 entry with $902M cash pile
Apogee Therapeutics (NASDAQ:APGE) solidified its clinical roadmap for 2026 on Monday, reporting a year-end cash position of $902.9 million.
Xeris Biopharma reports Q4 net income of $11.1M, beating estimates
Xeris Biopharma Holdings (NASDAQ:XERS), a Chicago-based specialty pharmaceutical company focused on therapies for rare endocrine and metabolic diseases, on Monday reported net income of $11.1 million for its fourth quarter ended December 31, 2025.
Health
uniQure pivots to Phase 3 planning for Huntington’s after FDA requests sham-controlled trial
uniQure (NASDAQ:QURE) entered 2026 with a dual narrative of clinical progress and regulatory complexity.
Health
Compugen swings to 2025 profit as AstraZeneca deal extends cash runway to 2029
Compugen (NASDAQ:CGEN) delivered a transformative fiscal 2025, reporting a sharp pivot to profitability and a significantly bolstered balance sheet.
Zymeworks nears commercial milestone with Ziihera as 2025 revenue climbs 39%
Zymeworks (NASDAQ:ZYME) reported a significant narrowing of its annual losses and a double-digit jump in revenue on Monday, driven by the continued maturation of its oncology-focused licensing portfolio.
Health
RadNet hits record $2B revenue mark as AI and advanced imaging surges
RadNet (NASDAQ:RDNT) reported record fourth-quarter and full-year 2025 results today, underscoring the success of its dual-track strategy to dominate both physical outpatient imaging and the burgeoning clinical AI market.
Belite Bio reports positive Phase 3 DRAGON results with 35.7% reduction in macular lesion
Belite Bio (NASDAQ:BLTE), a clinical-stage biopharmaceutical company focused on developing therapies for degenerative retinal diseases, today announced positive topline results from its pivotal Phase 3 DRAGON trial evaluating tinlarebant, an oral retinol binding protein 4 (RBP4) antagonist, for the treatment of adolescent Stargardt disease.